Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 2/20 | 0.31 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23957806 | 0.84 | EGLN2 (0.33) | NTRK1HRH4HRH3EGLN2GPR88 | |
| SCHEMBL13453642 | 0.82 | SMPD1 (0.41) | HRH4HRH3SMPD1GBA1 | |
| SCHEMBL19400545 | 0.82 | HRH4 (0.35) | HRH4HRH3SMPD1IRAK4GBA1 | |
| SCHEMBL26763404 | 0.81 | HRH4 (0.35) | NTRK1HRH4HRH3 | |
| SCHEMBL18089449 | 0.81 | HRH4 (0.35) | HRH4HRH3SMPD1IRAK4 | |
| SCHEMBL12364362 | 0.81 | HRH4 (0.35) | NTRK1HRH4HRH3 | |
| SCHEMBL19120293 | 0.80 | NTRK1 (0.42) | NTRK1MEN1KMT2AMAPK14 | |
| SCHEMBL25715688 | 0.79 | SMPD1 (0.42) | HRH4HRH3SMPD1GBA1 | |
| SCHEMBL12364369 | 0.78 | HRH4 (0.37) | HRH4HRH3SMPD1IRAK4 | |
| SCHEMBL21534048 | 0.78 | HRH4 (0.33) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174520-A1 | 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20210179592-A1 | 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | Grünenthal GmbH (DE) | 2021-06-17 | — | — | US | disclosed |
| US-10829480-B2 | 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives | GRUENENTHAL GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-10316017-B2 | COT modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180215727-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215727-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180193338-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9839639-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170197947-A1 | 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-13 | — | — | US | disclosed |
| US-20170197947-A1 | 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-13 | — | — | US | disclosed |
| US-20170189399-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | NTRK1 1824/4885MAPT 4689/4885HRH4 2806/4885 |
| US-20230174520-A1 | 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, ARRB1 | NTRK1 586/4885MAPT 3577/4885HRH4 1243/4885 |
| US-20210179592-A1 | 3-((HETERO-)ARYL)-ALKYL-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | OPRK1, OPRD1, ARRB1 | NTRK1 586/4885MAPT 3577/4885HRH4 1243/4885 |
| US-10316017-B2 | COT modulators and methods of use thereof | BRDT, THRB, HCCS | NTRK1 1824/4885MAPT 4689/4885HRH4 2806/4885 |
| US-20170197947-A1 | 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, ARRB1 | NTRK1 586/4885MAPT 3577/4885HRH4 1243/4885 |
| US-20180193338-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | NTRK1 467/4885MAPT 443/4885HRH4 349/4885 |
| US-20180215727-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | NTRK1 4611/4885MAPT 3741/4885HRH4 3482/4885 |
| US-10829480-B2 | 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives | OPRD1, OPRK1, OPRL1 | NTRK1 562/4885MAPT 3713/4885HRH4 1353/4885 |
| US-20170189399-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | NTRK1 467/4885MAPT 443/4885HRH4 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.